Signalling pathway may send cancer's cellular factories into overdrive

the ONA take:

Scientists identified a molecular trigger that prompts the unrestricted cell growth in cancer. A protein in the TOR signaling pathway, SREBP, controls the flow of messages to the endoplasmic reticulum (ER) to produce enough proteins and lipids to support nonstop growth. The ER creates the lipids and proteins all cells need to build new cells. In healthy cells, constant growth can overwhelm the ER and lead to cell stress and death, whereas cancer cells maintain a high level of activity in the ER, thereby fueling continuous growth. Scientists at The Institute of Cancer Research used the cells of fruit flies to identify the signals responsible for increasing activity of the ER. They systematically silenced genes thought to be important to ER function. When silencing the TOR signaling pathway, ER stress in the cells was increased and the cells died. “The TOR pathway is active in many types of cancer, and our study provides new insights into how cancer metabolism works, and suggests that these metabolic signals could be excellent targets for future treatments,” reported the researchers.

Signalling pathway may send cancer's cellular factories into overdrive
Signalling pathway may send cancer's cellular factories into overdrive
A network of signals active in almost all types of cancer sends the protein factories in our cells into overdrive, and may help fuel a tumour's uncontrolled growth, new research suggests. A protein in the TOR signalling pathway, called SREBP, controls the flow of messages to the endoplasmic reticulum telling it to expand – and could allow cancer cells to produce enough proteins and lipids to fuel their non-stop growth.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs